Tozorakimab trial success hands AstraZeneca a crucial edge in the race to crack COPD's hardest-to-treat patients [Yahoo! Finance]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: Yahoo! Finance
Friday's positive trial results for tozorakimab mark a significant inflexion point for AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) , arriving at a moment when the market had all but written off the drug's prospects and at a time when the pharmaceutical industry has been struggling to find treatments that work across the full spectrum of chronic obstructive pulmonary disease. COPD, a progressive lung condition affecting hundreds of millions of people worldwide, has long resisted a one-size-fits-all treatment approach, and the segment that has proved most stubborn is patients with low levels of eosinophils, a type of white blood cell, who account for roughly 35% of sufferers and for whom existing therapies offer limited benefit. It is precisely here that tozorakimab appears to have delivered, with AstraZeneca's OBERON and TITANIA studies showing clinically meaningful reductions in exacerbations across both eosinophil-high and eosinophil-low populations, as well as in former and current s
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- LLY to Buy Neuroscience Biotech Centessa Pharmaceuticals in $7.8B Deal [Yahoo! Finance]Yahoo! Finance
- Sanofi Gets EU Nod for Rezurock in Chronic Graft-Vs-Host Disease [Yahoo! Finance]Yahoo! Finance
- Press Release: Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host diseaseGlobeNewswire
- Sanofi Oncology And Rare Disease Updates Spark Fresh Valuation Interest [Yahoo! Finance]Yahoo! Finance
- Sanofi eczema drug weighed down by mixed results, safety concerns [Yahoo! Finance]Yahoo! Finance
SNY
Sec Filings
- 3/31/26 - Form 6-K
- 3/24/26 - Form 6-K
- 3/10/26 - Form 6-K
- SNY's page on the SEC website